ENTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Entera Bio Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$2.94+0.26 (+9.70%)
Close on Oct 19, 2026
- Market cap
- $148.33M
- P/E (TTM)
- 11.8
- Dividend yield
- –
Entera Bio statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Entera Bio | Industry median |
|---|---|---|
| Market Cap | $509.04M | $164.85M |
| Enterprise Value | $497.73M | $87.06M |
| PB Ratio | 70.06 | 2.03 |
| P/TBV Ratio | 70.06 | 2.31 |
Income (trailing twelve months)
| Measure | Entera Bio | Industry median |
|---|---|---|
| Revenue | $0 | $57.94M |
| Gross Profit | $0 | $90.47M |
| Operating Income | -$14.40M | -$21.44M |
| Net Income | -$17.03M | -$22.46M |
| EBITDA | -$14.40M | -$16.91M |
Returns
| Measure | Entera Bio | Industry median |
|---|---|---|
| Return on Equity (ROE) | -138.9% | -53.1% |
| Return on Assets (ROA) | -87.0% | -41.0% |
| Return on Invested Capital (ROIC) | -966.1% | -32.0% |
| Return on Capital Employed (ROCE) | -82.9% | -37.8% |
Growth
| Measure | Entera Bio | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -100.0% | 6.01% |
| Revenue Growth (3Y CAGR) | -32.1% | 2.25% |
| Revenue Growth (5Y CAGR) | -35.1% | 6.42% |
| EPS Growth (3Y CAGR) | -17.8% | -0.17% |
| EPS Growth (5Y CAGR) | -17.9% | 3.77% |
Balance sheet
| Measure | Entera Bio | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $11.31M | $62.42M |
| Net Cash (Debt) | $11.31M | $15.68M |
| Net Cash Per Share | $0.07 | $0.66 |
| Equity (Book Value) | $7.27M | $48.79M |
| Book Value Per Share | $0.04 | $1.36 |
| Tangible Book Value | $7.27M | $23.06M |
| Working Capital | $16.79M | $75.77M |
Financial position
| Measure | Entera Bio | Industry median |
|---|---|---|
| Current Ratio | 8.98 | 3.30 |
| Quick Ratio | 5.38 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Entera Bio | Industry median |
|---|---|---|
| Operating Cash Flow | -$10.89M | -$12.35M |
| Capital Expenditures | -$73.00K | -$1.06M |
| Free Cash Flow | -$10.96M | -$20.28M |
| FCF Per Share | -$0.06 | -$0.42 |
Efficiency
| Measure | Entera Bio | Industry median |
|---|---|---|
| Asset Turnover | 0.00 | 0.38 |
| Revenue Per Employee | $0 | $398.96K |
| Profits Per Employee | -$851.65K | -$703.34K |
| Employee Count | 20 | 74 |
Dividends and yields
| Measure | Entera Bio | Industry median |
|---|---|---|
| Earnings Yield | -3.35% | -22.7% |
| FCF Yield | -2.15% | -9.07% |
| Buyback Yield | -0.01% | -0.73% |
| Shareholder Yield | -0.01% | 0.00% |
Shares
| Measure | Entera Bio | Industry median |
|---|---|---|
| Shares Outstanding | 173,142,000 | 58,179,650 |
| Shares Change (YoY) | 15.3% | 11.1% |
| Shares Change (QoQ) | 5.72% | 0.54% |
| Float | 153,512,000 | 49,173,100 |
| Shares Held by Insiders | 11.3% | 11.6% |
Scores
| Measure | Entera Bio | Industry median |
|---|---|---|
| Altman Z-Score | 13.81 | -0.24 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Entera Bio's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.